Clinical Trial Readiness for Rare Diseases, Disorders, and Syndromes (R03, R21 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites researchers to submit applications for support of clinical projects that address critical needs for clinical trial readiness in rare diseases. The initiative seeks applications that are intended to facilitate rare disease research by enabling efficient and effective movement of candidate therapeutics or diagnostics towards clinical trials, and to increase their likelihood of success through development and testing of rigorous biomarkers and clinical outcome assessment measures, or by defining the presentation and course of a rare disease to enable the design of upcoming clinical trials.   

Although this funding opportunity uses the R03 grant mechanism, it runs in parallel with a program announcement of identical scientific scope, PAR-18-953, which uses the R21 grant mechanism.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s):  January 7, 2019, June 10, 2019, October 24, 2019, June 8, 2020, October 26, 2020, June 7, 2021, October 25, 2021

​PAR-18-952 Expiration Date October 26, 2021

Agency Website



Amount Description

Applications can request a project period of up to 2 years and a budget for direct costs of up $50,000 per year, but need to reflect the actual needs of the proposed project.

Funding Type





Medical - Clinical Science
Medical - Translational

External Deadline

June 8, 2020